Skip to main content
Top
Published in: The Patient - Patient-Centered Outcomes Research 4/2014

Open Access 01-12-2014 | Original Research Article

Barriers to Initiating Insulin in Type 2 Diabetes Patients: Development of a New Patient Education Tool to Address Myths, Misconceptions and Clinical Realities

Authors: Meryl Brod, Suzanne Lessard Alolga, Luigi Meneghini

Published in: The Patient - Patient-Centered Outcomes Research | Issue 4/2014

Login to get access

Abstract

Purpose

The purpose of this study was to identify patient beliefs as well as clinical realities about insulin that may be barriers to type 2 diabetes patients initiating insulin treatment when recommended by their physician. This information was then used to develop a clinically relevant, cross-culturally valid patient education tool with the goal of providing unbiased, medically informative statements addressing these barriers.

Methods

Thirteen focus groups were conducted in five countries (Germany, Sweden, The Netherlands, UK, and USA) to collect qualitative data on attitudes about insulin therapy from type 2 diabetes patients aged 18 or older whose physician had recommended initiating insulin treatment in the past 6 months (n = 87). Additionally, a panel of four clinical experts was interviewed to ascertain obstacles they experience in initiating insulin with their patients.

Results

On the basis of the interview data, the ten questions that asked about the most important barriers were generated. The clinical expert panel then generated clinically accurate and unbiased responses addressing these concerns, and the educational tool “Questions about Starting Insulin: Information on the Myths, Misconceptions and Clinical Realities about Insulin” was drafted. The draft tool was pilot tested in a group of patients and finalized.

Conclusions

Patient misconceptions, as well as some clinical realities, about insulin treatment and diabetes can influence the decision to initiate insulin treatment and ultimately impact disease management. The educational tool developed through this study was designed to help patients who are deciding whether or not to initiate insulin therapy as recommended by their physician, and facilitate patient–health-care provider interactions.
Literature
1.
go back to reference Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378(9785):31–40.PubMedCrossRef Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378(9785):31–40.PubMedCrossRef
3.
go back to reference Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.” BMJ. 2000;321:405–12.PubMedCentralPubMedCrossRef Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.” BMJ. 2000;321:405–12.PubMedCentralPubMedCrossRef
4.
go back to reference Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.PubMedCentralPubMedCrossRef Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.PubMedCentralPubMedCrossRef
5.
go back to reference Logtenberg SJ, Kleefstra N, Ubink-Veltmaat LJ, Houweling ST, Bilo HJ. Intensification of therapy and no increase in body mass index with longer disease duration in type 2 diabetes mellitus (ZODIAC-5). Fam Pract. 2007;24:529–31.PubMedCrossRef Logtenberg SJ, Kleefstra N, Ubink-Veltmaat LJ, Houweling ST, Bilo HJ. Intensification of therapy and no increase in body mass index with longer disease duration in type 2 diabetes mellitus (ZODIAC-5). Fam Pract. 2007;24:529–31.PubMedCrossRef
6.
go back to reference de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn study. Diabetologia. 1999;42:926–31.PubMedCrossRef de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn study. Diabetologia. 1999;42:926–31.PubMedCrossRef
7.
go back to reference Wild SH, Smith FB, Lee AJ, Fowkes FG. Criteria for previously undiagnosed diabetes and risk of mortality: 15-year follow-up of the Edinburgh Artery Study cohort. Diabet Med. 2005;22:490–6.PubMedCrossRef Wild SH, Smith FB, Lee AJ, Fowkes FG. Criteria for previously undiagnosed diabetes and risk of mortality: 15-year follow-up of the Edinburgh Artery Study cohort. Diabet Med. 2005;22:490–6.PubMedCrossRef
8.
go back to reference Meneghini L. Why and how to use insulin therapy earlier in the management of type 2 diabetes. South Med J. 2007;100:164–74.PubMedCrossRef Meneghini L. Why and how to use insulin therapy earlier in the management of type 2 diabetes. South Med J. 2007;100:164–74.PubMedCrossRef
9.
go back to reference Lingvay I, Kaloyanova PF, Adams-Huet B, Salinas K, Raskin P. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Investig Med. 2007;55:62–8.PubMedCrossRef Lingvay I, Kaloyanova PF, Adams-Huet B, Salinas K, Raskin P. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Investig Med. 2007;55:62–8.PubMedCrossRef
10.
go back to reference UK Prospective Diabetes Study 16. Overview of 6 years’ therapy of type 2 diabetes: a progressive disease. UK Prospective Diabetes Study Group [erratum in Diabetes. 1996;45:1655]. Diabetes. 1995;44:1249–58.CrossRef UK Prospective Diabetes Study 16. Overview of 6 years’ therapy of type 2 diabetes: a progressive disease. UK Prospective Diabetes Study Group [erratum in Diabetes. 1996;45:1655]. Diabetes. 1995;44:1249–58.CrossRef
11.
go back to reference Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17–20.PubMedCrossRef Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17–20.PubMedCrossRef
12.
go back to reference Brod M, Kongsø JH, Lessard S, Christensen TL. Psychological insulin resistance: patient beliefs and implications for diabetes management. Qual Life Res. 2009;18:23–32.PubMedCrossRef Brod M, Kongsø JH, Lessard S, Christensen TL. Psychological insulin resistance: patient beliefs and implications for diabetes management. Qual Life Res. 2009;18:23–32.PubMedCrossRef
13.
go back to reference Larkin ME, Capasso VA, Chen CL, Mahoney EK, Hazard B, Cagliero E, et al. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ. 2008;34:511–7.PubMedCrossRef Larkin ME, Capasso VA, Chen CL, Mahoney EK, Hazard B, Cagliero E, et al. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ. 2008;34:511–7.PubMedCrossRef
14.
go back to reference Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28:2543–5.PubMedCrossRef Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28:2543–5.PubMedCrossRef
15.
go back to reference Wang HF, Yeh MC. Psychological resistance to insulin therapy in adults with type 2 diabetes: mixed-method systematic review. J Adv Nurs. 2012;68:743–57.PubMedCrossRef Wang HF, Yeh MC. Psychological resistance to insulin therapy in adults with type 2 diabetes: mixed-method systematic review. J Adv Nurs. 2012;68:743–57.PubMedCrossRef
16.
go back to reference Woudenberg YJ, Lucas C, Latour C, Scholte op Reimer WJ. Acceptance of insulin therapy: a long shot? Psychological insulin resistance in primary care. Diabet Med. 2012;29:796–802.PubMedCrossRef Woudenberg YJ, Lucas C, Latour C, Scholte op Reimer WJ. Acceptance of insulin therapy: a long shot? Psychological insulin resistance in primary care. Diabet Med. 2012;29:796–802.PubMedCrossRef
17.
go back to reference Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673–9.PubMedCrossRef Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673–9.PubMedCrossRef
18.
go back to reference Nathan DM. Clinical practice: initial management of glycemia in type 2 diabetes mellitus. N Engl J Med. 2002;347:1342–9.PubMedCrossRef Nathan DM. Clinical practice: initial management of glycemia in type 2 diabetes mellitus. N Engl J Med. 2002;347:1342–9.PubMedCrossRef
19.
go back to reference Davis SN, Renda SM. Psychological insulin resistance: overcoming barriers to starting insulin therapy. Diabetes Educ. 2006;32:146S–52S.PubMedCrossRef Davis SN, Renda SM. Psychological insulin resistance: overcoming barriers to starting insulin therapy. Diabetes Educ. 2006;32:146S–52S.PubMedCrossRef
20.
go back to reference Ishii H, Iwamoto Y, Tajima N. An exploration of barriers to insulin initiation for physicians in Japan: findings from the Diabetes Attitudes, Wishes and Needs (DAWN) Japan study. PLoS One. 2012;7:e36361.PubMedCentralPubMedCrossRef Ishii H, Iwamoto Y, Tajima N. An exploration of barriers to insulin initiation for physicians in Japan: findings from the Diabetes Attitudes, Wishes and Needs (DAWN) Japan study. PLoS One. 2012;7:e36361.PubMedCentralPubMedCrossRef
21.
go back to reference Ratanawongsa N, Crosson JC, Schillinger D, Karter AJ, Saha CK, Marrero DG. Getting under the skin of clinical inertia in insulin initiation: the Translating Research Into Action for Diabetes (TRIAD) Insulin Starts Project. Diabetes Educ. 2012;38:94–100.PubMedCentralPubMedCrossRef Ratanawongsa N, Crosson JC, Schillinger D, Karter AJ, Saha CK, Marrero DG. Getting under the skin of clinical inertia in insulin initiation: the Translating Research Into Action for Diabetes (TRIAD) Insulin Starts Project. Diabetes Educ. 2012;38:94–100.PubMedCentralPubMedCrossRef
22.
go back to reference Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med. 2001;161:1653–9.PubMedCrossRef Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med. 2001;161:1653–9.PubMedCrossRef
23.
go back to reference Riddle MC. The underuse of insulin therapy in North America. Diabetes Metab Res Rev. 2002;18(Suppl 3):S42–9.PubMedCrossRef Riddle MC. The underuse of insulin therapy in North America. Diabetes Metab Res Rev. 2002;18(Suppl 3):S42–9.PubMedCrossRef
24.
go back to reference Karter AJ, Subramanian U, Saha C, Crosson JC, Parker MM, Swain BE, et al. Barriers to insulin initiation: the Translating Research Into Action for Diabetes Insulin Starts Project. Diabetes Care. 2010;33:733–5.PubMedCentralPubMedCrossRef Karter AJ, Subramanian U, Saha C, Crosson JC, Parker MM, Swain BE, et al. Barriers to insulin initiation: the Translating Research Into Action for Diabetes Insulin Starts Project. Diabetes Care. 2010;33:733–5.PubMedCentralPubMedCrossRef
25.
go back to reference Funnell MM. Overcoming barriers to the initiation of insulin therapy. Clin Diabetes. 2007;25:36–8.CrossRef Funnell MM. Overcoming barriers to the initiation of insulin therapy. Clin Diabetes. 2007;25:36–8.CrossRef
26.
go back to reference Lawton J, Peel E, Parry O, Douglas M. Patients’ perceptions and experiences of taking oral glucose-lowering agents: a longitudinal qualitative study. Diabet Med. 2008;25:491–5.PubMedCrossRef Lawton J, Peel E, Parry O, Douglas M. Patients’ perceptions and experiences of taking oral glucose-lowering agents: a longitudinal qualitative study. Diabet Med. 2008;25:491–5.PubMedCrossRef
28.
go back to reference Gucciardi E, Fortugno M, Senchuk A, Beanlands H, McCay E, Peel EE. Self-monitoring of blood glucose in Black Caribbean and South Asian Canadians with non-insulin treated type 2 diabetes mellitus: a qualitative study of patients’ perspectives. BMC Endocr Disord. 2013. doi:10.1186/1472-6823-13-46.PubMedCentralPubMed Gucciardi E, Fortugno M, Senchuk A, Beanlands H, McCay E, Peel EE. Self-monitoring of blood glucose in Black Caribbean and South Asian Canadians with non-insulin treated type 2 diabetes mellitus: a qualitative study of patients’ perspectives. BMC Endocr Disord. 2013. doi:10.​1186/​1472-6823-13-46.PubMedCentralPubMed
29.
go back to reference Hortensius J, Kars MC, Wierenga WS, Kleefstra N, Bilo HJ, van der Bijl JJ. Perspectives of patients with type 1 or insulin-treated type 2 diabetes on self-monitoring of blood glucose: a qualitative study. BMC Public Health. 2012. doi:10.1186/1471-2458-12-167.PubMedCentralPubMed Hortensius J, Kars MC, Wierenga WS, Kleefstra N, Bilo HJ, van der Bijl JJ. Perspectives of patients with type 1 or insulin-treated type 2 diabetes on self-monitoring of blood glucose: a qualitative study. BMC Public Health. 2012. doi:10.​1186/​1471-2458-12-167.PubMedCentralPubMed
30.
go back to reference Peel E, Parry O, Douglas M, Lawton J. Blood glucose self-monitoring in non-insulin-treated type 2 diabetes: a qualitative study of patients’ perspectives. Br J Gen Pract. 2004;54:183–8.PubMedCentralPubMed Peel E, Parry O, Douglas M, Lawton J. Blood glucose self-monitoring in non-insulin-treated type 2 diabetes: a qualitative study of patients’ perspectives. Br J Gen Pract. 2004;54:183–8.PubMedCentralPubMed
31.
go back to reference Peel E, Douglas M, Lawton J. Self monitoring of blood glucose in type 2 diabetes: longitudinal qualitative study of patients’ perspectives. BMJ. 2007;335:493.PubMedCentralPubMedCrossRef Peel E, Douglas M, Lawton J. Self monitoring of blood glucose in type 2 diabetes: longitudinal qualitative study of patients’ perspectives. BMJ. 2007;335:493.PubMedCentralPubMedCrossRef
32.
go back to reference Beverly E, Ritholz M, Brooks K, Hultgren B, Lee Y, Abrahamson M, et al. A qualitative study of perceived responsibility and self-blame in type 2 diabetes: reflections of physicians and patients. J Gen Intern Med. 2012;27:1180–7.PubMedCentralPubMedCrossRef Beverly E, Ritholz M, Brooks K, Hultgren B, Lee Y, Abrahamson M, et al. A qualitative study of perceived responsibility and self-blame in type 2 diabetes: reflections of physicians and patients. J Gen Intern Med. 2012;27:1180–7.PubMedCentralPubMedCrossRef
33.
go back to reference Carbone ET, Rosal MC, Torres MI, Goins KV, Bermudez OI. Diabetes self-management: perspectives of Latino patients and their health care providers. Patient Educ Couns. 2007;66:202–10.PubMedCrossRef Carbone ET, Rosal MC, Torres MI, Goins KV, Bermudez OI. Diabetes self-management: perspectives of Latino patients and their health care providers. Patient Educ Couns. 2007;66:202–10.PubMedCrossRef
34.
go back to reference Nagelkerk J, Reick K, Meengs L. Perceived barriers and effective strategies to diabetes self-management. J Adv Nurs. 2006;54:151–8.PubMedCrossRef Nagelkerk J, Reick K, Meengs L. Perceived barriers and effective strategies to diabetes self-management. J Adv Nurs. 2006;54:151–8.PubMedCrossRef
35.
go back to reference Rosenstock IM, Strecher VJ, Becker MH. Social learning theory and the Health Belief Model. Health Educ Q. 1988;15:175–83.PubMedCrossRef Rosenstock IM, Strecher VJ, Becker MH. Social learning theory and the Health Belief Model. Health Educ Q. 1988;15:175–83.PubMedCrossRef
36.
go back to reference Harvey JN, Lawson VL. The importance of health belief models in determining self-care behaviour in diabetes. Diabet Med. 2009;26:5–13.PubMedCrossRef Harvey JN, Lawson VL. The importance of health belief models in determining self-care behaviour in diabetes. Diabet Med. 2009;26:5–13.PubMedCrossRef
37.
go back to reference Champion V, Skinner CS. The Health Belief Model. In: Glanz K, Rimer BK, Viswanath K, editors. Health behavior and health education: theory, research, and practice. San Francisco: Jossey-Bass; 2008. p. 45–65. Champion V, Skinner CS. The Health Belief Model. In: Glanz K, Rimer BK, Viswanath K, editors. Health behavior and health education: theory, research, and practice. San Francisco: Jossey-Bass; 2008. p. 45–65.
38.
go back to reference Hayden JA. Introduction to health behavior theory. 2nd ed. Burlington: Jones & Bartlett Learning; 2014. Hayden JA. Introduction to health behavior theory. 2nd ed. Burlington: Jones & Bartlett Learning; 2014.
39.
go back to reference Brod M, Tesler LE, Christensen T. Qualitative research and content validity: developing best practices based on science and experience. Qual Life Res. 2009;18:1263–78.PubMedCrossRef Brod M, Tesler LE, Christensen T. Qualitative research and content validity: developing best practices based on science and experience. Qual Life Res. 2009;18:1263–78.PubMedCrossRef
40.
go back to reference Saldana J. The coding manual for qualitative researchers. Los Angeles: Sage; 2010. Saldana J. The coding manual for qualitative researchers. Los Angeles: Sage; 2010.
41.
go back to reference Frost MH, Reeve BB, Liepa AM, Stauffer JW, Hays RD, Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. What is sufficient evidence for the reliability and validity of patient-reported outcome measures? Value Health. 2007;10:S94–105.PubMedCrossRef Frost MH, Reeve BB, Liepa AM, Stauffer JW, Hays RD, Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. What is sufficient evidence for the reliability and validity of patient-reported outcome measures? Value Health. 2007;10:S94–105.PubMedCrossRef
47.
go back to reference UK Prospective Diabetes (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef UK Prospective Diabetes (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef
50.
go back to reference Johns Hopkins Medicine. Insulin therapy: friend, not foe. It’s time to dispel common myths about insulin treatment for people with type 2 diabetes. Johns Hopkins Med Lett Health After. 2011;23:4–5. Johns Hopkins Medicine. Insulin therapy: friend, not foe. It’s time to dispel common myths about insulin treatment for people with type 2 diabetes. Johns Hopkins Med Lett Health After. 2011;23:4–5.
51.
go back to reference Minze MG, Dalal K, Irons BK. Removing barriers to insulin use. J Fam Pract. 2011;60:577–80.PubMed Minze MG, Dalal K, Irons BK. Removing barriers to insulin use. J Fam Pract. 2011;60:577–80.PubMed
52.
go back to reference Peyrot M, Rubin RR, Khunit K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes. 2010;4:S11–8.PubMedCrossRef Peyrot M, Rubin RR, Khunit K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes. 2010;4:S11–8.PubMedCrossRef
54.
go back to reference Alberti G. The DAWN (Diabetes Attitudes, Wishes and Needs) study. Pract Diab Int. 2002;19:22–4a. Alberti G. The DAWN (Diabetes Attitudes, Wishes and Needs) study. Pract Diab Int. 2002;19:22–4a.
55.
go back to reference Skovlund SE, Peyrot M. The Diabetes Attitudes, Wishes, and Needs (DAWN) program: a new approach to improving outcomes of diabetes care. Diabetes Spectrum. 2005;18:136–42.CrossRef Skovlund SE, Peyrot M. The Diabetes Attitudes, Wishes, and Needs (DAWN) program: a new approach to improving outcomes of diabetes care. Diabetes Spectrum. 2005;18:136–42.CrossRef
56.
go back to reference Skovlund SE. Diabetes attitudes, wishes and needs. Diabetes Voice. 2004;49:4–11. Skovlund SE. Diabetes attitudes, wishes and needs. Diabetes Voice. 2004;49:4–11.
57.
go back to reference Hermanns N, Mahr M, Kulzer B, Skovlund SE, Haak T. Barriers towards insulin therapy in type 2 diabetic patients: results of an observational longitudinal study. Health Qual Life Outcomes. 2010;8:113.PubMedCentralPubMedCrossRef Hermanns N, Mahr M, Kulzer B, Skovlund SE, Haak T. Barriers towards insulin therapy in type 2 diabetic patients: results of an observational longitudinal study. Health Qual Life Outcomes. 2010;8:113.PubMedCentralPubMedCrossRef
58.
go back to reference Ruiz MA, Pardo A, Martinez de la Casa JM, Polo V, Esquiro J, Soto J. Development of a specific questionnaire measuring patient satisfaction with glaucoma treatment: Glausat. Ophthalmic Epidemiol. 2010;17:131–43.PubMedCrossRef Ruiz MA, Pardo A, Martinez de la Casa JM, Polo V, Esquiro J, Soto J. Development of a specific questionnaire measuring patient satisfaction with glaucoma treatment: Glausat. Ophthalmic Epidemiol. 2010;17:131–43.PubMedCrossRef
59.
go back to reference Dréno B, Thiboutot D, Gollnick H, Finlay AY, Layton A, Leyden JJ, et al. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol. 2010;49:448–56.PubMedCrossRef Dréno B, Thiboutot D, Gollnick H, Finlay AY, Layton A, Leyden JJ, et al. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol. 2010;49:448–56.PubMedCrossRef
60.
go back to reference Biderman A, Noff E, Harris SB, Friedman N, Levy A. Treatment satisfaction of diabetic patients: what are the contributing factors? Fam Pract. 2009;26:102–8.PubMedCrossRef Biderman A, Noff E, Harris SB, Friedman N, Levy A. Treatment satisfaction of diabetic patients: what are the contributing factors? Fam Pract. 2009;26:102–8.PubMedCrossRef
61.
go back to reference Testa MA, Simonson DC. Satisfaction and quality of life with premeal inhaled versus injected insulin in adolescents and adults with type 1 diabetes. Diabetes Care. 2007;30:1399–405.PubMedCrossRef Testa MA, Simonson DC. Satisfaction and quality of life with premeal inhaled versus injected insulin in adolescents and adults with type 1 diabetes. Diabetes Care. 2007;30:1399–405.PubMedCrossRef
62.
go back to reference Brod M, Cobden D, Lammert M, Bushnell D, Raskin P. Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. Health Qual Life Outcomes. 2007;5:8.PubMedCentralPubMedCrossRef Brod M, Cobden D, Lammert M, Bushnell D, Raskin P. Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. Health Qual Life Outcomes. 2007;5:8.PubMedCentralPubMedCrossRef
63.
go back to reference Brod M, Skovlund SE, Wittrup-Jensen KU. Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience. Qual Life Res. 2006;15:481–91.PubMedCrossRef Brod M, Skovlund SE, Wittrup-Jensen KU. Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience. Qual Life Res. 2006;15:481–91.PubMedCrossRef
64.
go back to reference Casciano R, Malangone E, Ramachandran A, Gagliardino JJ. A quantitative assessment of patient barriers to insulin. Int J Clin Pract. 2011;65:408–14.PubMedCrossRef Casciano R, Malangone E, Ramachandran A, Gagliardino JJ. A quantitative assessment of patient barriers to insulin. Int J Clin Pract. 2011;65:408–14.PubMedCrossRef
65.
go back to reference Martinez L, Consoli SM, Monnier L, Simon D, Wong O, Yomtov B, et al. Studying the Hurdles of Insulin Prescription (SHIP): development, scoring and initial validation of a new self-administered questionnaire. Health Qual Life Outcomes. 2007;5:53.PubMedCentralPubMedCrossRef Martinez L, Consoli SM, Monnier L, Simon D, Wong O, Yomtov B, et al. Studying the Hurdles of Insulin Prescription (SHIP): development, scoring and initial validation of a new self-administered questionnaire. Health Qual Life Outcomes. 2007;5:53.PubMedCentralPubMedCrossRef
66.
go back to reference Snoek FJ, Skovlund SE, Pouwer F. Development and validation of the Insulin Treatment Appraisal Scale (ITAS) in patients with type 2 diabetes. Health Qual Life Outcomes. 2007;20(5):69.CrossRef Snoek FJ, Skovlund SE, Pouwer F. Development and validation of the Insulin Treatment Appraisal Scale (ITAS) in patients with type 2 diabetes. Health Qual Life Outcomes. 2007;20(5):69.CrossRef
Metadata
Title
Barriers to Initiating Insulin in Type 2 Diabetes Patients: Development of a New Patient Education Tool to Address Myths, Misconceptions and Clinical Realities
Authors
Meryl Brod
Suzanne Lessard Alolga
Luigi Meneghini
Publication date
01-12-2014
Publisher
Springer International Publishing
Published in
The Patient - Patient-Centered Outcomes Research / Issue 4/2014
Print ISSN: 1178-1653
Electronic ISSN: 1178-1661
DOI
https://doi.org/10.1007/s40271-014-0068-x

Other articles of this Issue 4/2014

The Patient - Patient-Centered Outcomes Research 4/2014 Go to the issue

Acknowledgement to Referees

Acknowledgement to Referees